DEMOGRAPHIC AND PATHOLOGICAL CHARACTERISTICS OF GASTRIC CARCINOMAS – A Three-Year Single Center Experience
Introduction:Despite the decline in incidence and mortality rate in recent years, gastric carcinoma (GC) remains one of the leading causes of cancer-related deaths worldwide, especially in developing countries. The aim of this study was to present the clinic-pathological characteristics of gastric carcinomas in Patients in R. of North Macedonia. Material and methods: One hundred and forty-nine patients with gastric carcinoma were included in the study. Sixty-one patients underwent subtotal gastric resection with lymphadenectomy, and 88 patients underwent total gastrectomy with lymphadenectomy. For every patient tumor localization, TNM classification, grade and stage were determined. The parameters of the TNM classification (AJCC Cancer Staging 2017) were obtained from the archive histopathological reports of the Institute of Pathology in Skopje, and for the clinical stage, we used patient’s files from the University Clinic for Abdominal Surgery in Skopje. Results:The most common intragastric location of gastric carcinomas was cardia in 61 (40.94%) patients, followed by antral/pyloric carcinoma location in 51 (34.23%) patients and corpus location in 37 (24.83%) patients. According to the T state (local tumor growth), more than half of the examined patients 84 (56.38%) were in T4 state of the disease. Presence of positive regional lymph nodes was detected in 113 (75.84) patients, and negative in 36 (24.16%) patients. The majority of the patients that comprised the analyzed group had poor differentiated gastric carcinoma 81 (54.36%), and 88 (59.06%) were in Stage III of the disease.
Key words: gastric carinoma, TNM, grade, stage
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69 90.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.
4. Lee HE, Chae SW, Lee YJ, et al. Prognostic implications of type and density of tumor-infiltrating lymphocytes in
gastric cancer. BJC. 2008; 99:1704–11.
5. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis (Review)
Oncology L etters 2015; 9: 1502-08
6. Chung HW, Noh SH, LimJ-B. Analysis of demographic characteristics in 3242 young age gastric cancer patients
in Korea, World J Gastroenterol. 2010; 16(2): 256–63.
7. Hu B, El Hjj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J
Gastrointest Oncol. 2012; 3(3): 251–61
8. Yasui W, Sentani K, Sakamoto N. at al. Molecular pathology of gastric cancer, research and practice. Pathol Res
Pract 2011, 207:608-12.
9. Elimova E, Wadhwa R, Shiozaki H, Molecular Biomarkers in Gastric Cancer. J Natl Compr Canc Netw
10. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals
of Oncology. 2008; 19:1523–29.
11. Chandrasoma PT, Der R, Ma Y, et al. Histology of the gastroesophageal junction: an autopsy study. Am J Surg
12. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future
of TNM. 2010
13. Pesic M, Karanikolic A, Gjorgjevic N, et al. The Importance of Primary Gastric Cancer Location In 5-Year
Survival Rate, Arch Oncol 2004;12(Suppl 1):51-53
14. Badgwell B, Das P, Ajani J.Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of
accurate staging and preoperative therapy; J Hematol Oncol. 2017; 10: 149.
15. Patrick JT, Venkatesh SK. Gastric carcinoma: imaging diagnosis, staging and assessment of treatment
response. Cancer Imaging 2013; 13(2): 212–27
16. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–15.